Competing interests - None
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Memory and language deficits in patients receiving chemotherapy have been noted; however, the aetiology is unknown. Particularly in the treatment of breast cancer, confounding factors include hormone therapy, and stress and anxiety during treatment. There are inconsistencies among clinical researchers over the neuropsychological correlates present in cancer survivors with some reports indicating that only a minority of patients have cognitive deficits that interfere with their every day life (Shilling & Jenkins, 2007).Evidence from MRI scans of brain damage following radiotherapy and chemotherapy has been reported (Stewart, Bielajew, Collins, Parkinson, & Tomiak, 2006). Cognitive impairment, irrespective of education, profession, mood, or clinical characteristics, was found in terms of processing speed, attention, and learning (Wefel, Lenzi, Teriault, Davis & Meyers, 2004). Despite being subtle, these cognitive deficits led to functional loss manifested in decreased ability to work which is also associated with central toxicity.Yet others have not found any difference in cognitive performance when comparing cardiac patients with cancer survivors and matched controls (Mehlsen, Pedersen, Jensen & Zachariae, 2009). The idea that patients may be conditioned to eliciting cognitive deficits as responses has also been proposed (Bovbjerg, Redd, Maier, Holland, Lesko & Niedzwiecki, 1990).Receiving chemotherapy may function as a conditioned response giving rise to cognitive deficits and subsequent immunosuppression. Conditioned immuno-suppressionmay explain some of the undesirable and distressing effects of chemotherapy such as nausea, though this line of explanation is not entirely popular in light of the known toxicity of pharmaceuticals used in treatment of cancer patients.The authors would welcome information and data to assist with their enquiry.
1. Shilling V, Jenkins V, 2007. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. European Journal of Oncology Nursing. Vol 11, No 1, 6-15.2. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E, 2006. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clinical Neuropsychology. Vol 20, No 1, 79-89.3. Wefel J, Lenzi R, Teriault R, Davis R, & Meyers C A, 2004. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of prospective, randomized, longitudinal trial. Cancer. Vol 100, 2292â9.4. Mehlsen M, Pedersen A, Jensen A, Zachariae R, 2009. No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psycho-Oncology. Vol 18, 248â57.5. Bovbjerg D, Redd W, Maier L, Holland J, Lesko L, Niedzwiecki D, 1990. Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer. Journal of Consulting & Clinical Psychology. Vol 58, No 2, 153-157.